{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T15:49:34Z","timestamp":1787240974903,"version":"build-2736575974"},"reference-count":43,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,9,12]],"date-time":"2022-09-12T00:00:00Z","timestamp":1662940800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>As the strongest prodromal marker of \u03b1-synuclein-specific neurodegeneration, idiopathic REM sleep behavior disorder (iRBD) is becoming a focus of interest in disease-modifying therapy. Idebenone has been widely portrayed as a potent antioxidant targeting mitochondrial dysfunction. Previous study has identified the effect of idebenone on Parkinson's disease with promising outcomes by regulating mitophagy. A novel indication of idebenone should be highlighted in iRBD population.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>The EITRS study is a randomized, double-blind, multi-center clinical study assessing the efficacy and safety of idebenone in the treatment of iRBD into synucleinopathies. One hundred forty-two patients (aged 40\u201375 years old) with clinically diagnosed iRBD are planned to be recruited with 80% statistical power and randomly assigned to idebenone (30 mg each time, three times a day) or matching placebo orally for 5 years. The assessment of rating scales, blood testing and neuroimaging examinations will be conducted at baseline, the 1st, 3rd and 5th year of follow-up. The primary efficacy endpoint is the 5-year conversion rate in patients with iRBD. The secondary endpoint is the safety and tolerability of idebenone in the treatment of iRBD. The study has been launched in July 2020.<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>This is the first prospective study designed to identify the efficacy and safety of idebenone on the treatment of iRBD into synucleinopathies. The current results are expected to promote the development of evidence-based recommendations for the management of patients with iRBD. Furthermore, we hope to provide insights on a possible disease-modifying approach with robust evidence.<\/jats:p><\/jats:sec><jats:sec><jats:title>Trial Registration<\/jats:title><jats:p><jats:ext-link>Clinicaltrials.gov<\/jats:ext-link>, identifier: NCT 04534023.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fneur.2022.981249","type":"journal-article","created":{"date-parts":[[2022,9,12]],"date-time":"2022-09-12T07:15:46Z","timestamp":1662966946000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":14,"title":["Efficacy of idebenone in the Treatment of iRBD into Synucleinopathies (EITRS): rationale, design, and methodology of a randomized, double-blind, multi-center clinical study"],"prefix":"10.3389","volume":"13","author":[{"given":"Yuanyuan","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunyi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ningdi","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fangzheng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liche","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengyue","family":"Niu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenyan","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,9,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1038\/s41572-018-0016-5","article-title":"Sleep behaviour disorder","volume":"4","author":"Dauvilliers","year":"2018","journal-title":"Nat Rev Dis Primers."},{"key":"B2","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1038\/nrneurol.2017.157","article-title":"Idiopathic REM sleep behaviour disorder and neurodegeneration - an update","volume":"14","author":"Hogl","year":"2018","journal-title":"Nat Rev Neurol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s13024-021-00501-z","article-title":"Neuropathology and molecular diagnosis of synucleinopathies","volume":"16","author":"Koga","year":"2021","journal-title":"Mol Neurodegener."},{"key":"B4","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.smrv.2018.09.008","article-title":"The risk of neurodegeneration in REM sleep behavior disorder: a systematic review and meta-analysis of longitudinal studies","volume":"43","author":"Galbiati","year":"2019","journal-title":"Sleep Med Rev."},{"key":"B5","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/S1474-4422(21)00176-9","article-title":"Biomarkers of conversion to \u03b1-synucleinopathy in isolated rapid-eye-movement sleep behaviour disorder","volume":"20","author":"Miglis","year":"2021","journal-title":"Lancet Neurol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1002\/mds.27003","article-title":"Degeneration of rapid eye movement sleep circuitry underlies rapid eye movement sleep behavior disorder","volume":"32","author":"McKenna","year":"2017","journal-title":"Mov Disord."},{"key":"B7","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/j.tins.2014.02.009","article-title":"Breakdown in REM sleep circuitry underlies REM sleep behavior disorder","volume":"37","author":"Peever","year":"2014","journal-title":"Trends Neurosci."},{"key":"B8","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1002\/mds.27018","article-title":"REM sleep behavior disorder in Parkinson's disease and other synucleinopathies","volume":"32","author":"St Louis","year":"2017","journal-title":"Mov Disord."},{"key":"B9","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1136\/jnnp-2016-314471","article-title":"Sleep behaviour disorder: prodromal and mechanistic insights for Parkinson's disease","volume":"88","author":"Tekriwal","year":"2017","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"B10","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.smrv.2008.11.003","article-title":"The clinical and pathophysiological relevance of REM sleep behavior disorder in neurodegenerative diseases","volume":"13","author":"Iranzo","year":"2009","journal-title":"Sleep Med Rev."},{"key":"B11","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1001\/jamaneurol.2014.4563","article-title":"Rapid eye movement sleep behavior disorder and neurodegenerative disease","volume":"72","author":"Howell","year":"2015","journal-title":"JAMA Neurol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1093\/brain\/awz030","article-title":"Risk and predictors of dementia and parkinsonism in idiopathic REM sleep behaviour disorder: a multicentre study","volume":"142","author":"Postuma","year":"2019","journal-title":"Brain."},{"key":"B13","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1002\/ana.26298","article-title":"Risk factors for phenoconversion in rapid eye movement sleep behavior disorder","volume":"91","author":"Zhang","year":"2022","journal-title":"Ann Neurol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/S1474-4422(16)00057-0","article-title":"Idiopathic rapid eye movement sleep behaviour disorder: diagnosis, management, and the need for neuroprotective interventions","volume":"15","author":"Iranzo","year":"2016","journal-title":"Lancet Neurol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1016\/j.mayocp.2017.09.007","article-title":"Future directions","volume":"92","author":"Diagnosis","year":"2017","journal-title":"Mayo Clin Proc."},{"key":"B16","doi-asserted-by":"publisher","first-page":"zsx080","DOI":"10.1093\/sleep\/zsx080","article-title":"REM Sleep EEG instability in REM sleep behavior disorder and clonazepam effects","volume":"40","author":"Ferri","year":"2017","journal-title":"Sleep"},{"key":"B17","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.sleep.2014.09.011","article-title":"Melatonin therapy for REM sleep behavior disorder: a critical review of evidence","volume":"16","author":"McGrane","year":"2015","journal-title":"Sleep Med."},{"key":"B18","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1002\/mds.27886","article-title":"Melatonin for rapid eye movement sleep behavior disorder in Parkinson's disease: a randomised controlled trial","volume":"35","author":"Gilat","year":"2020","journal-title":"Mov Disord."},{"key":"B19","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.tibs.2020.11.007","article-title":"Mitochondrial dysfunction and mitophagy in parkinson's disease: from mechanism to therapy","volume":"46","author":"Malpartida","year":"2021","journal-title":"Trends Biochem Sci."},{"key":"B20","doi-asserted-by":"publisher","first-page":"101812","DOI":"10.1016\/j.redox.2020.101812","article-title":"Idebenone: when an antioxidant is not an antioxidant","volume":"38","author":"Gueven","year":"2021","journal-title":"Redox Biol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1038\/s41420-022-00826-8","article-title":"Idebenone improves motor dysfunction, learning and memory by regulating mitophagy in MPTP-treated mice","volume":"8","author":"Yan","year":"2022","journal-title":"Cell Death Discov."},{"key":"B22","doi-asserted-by":"publisher","first-page":"529","DOI":"10.3389\/fncel.2018.00529","article-title":"Idebenone alleviates neuroinflammation and modulates microglial polarization in LPS-stimulated BV2 Cells and MPTP-induced Parkinson's disease mice","volume":"12","author":"Yan","year":"2018","journal-title":"Front Cell Neurosci."},{"key":"B23","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1007\/s11064-020-03186-w","article-title":"Idebenone ameliorates rotenone-induced Parkinson's disease in rats through decreasing lipid peroxidation","volume":"46","author":"Avci","year":"2021","journal-title":"Neurochem Res."},{"key":"B24","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1007\/s12640-011-9245-z","article-title":"Idebenone induces apoptotic cell death in the human dopaminergic neuroblastoma SHSY-5Y cells","volume":"20","author":"Tai","year":"2011","journal-title":"Neurotox Res."},{"key":"B25","doi-asserted-by":"publisher","first-page":"8548380","DOI":"10.1155\/2021\/8548380","article-title":"Idebenone-activating autophagic degradation of alpha-synuclein via Inhibition of AKT-mTOR pathway in a SH-SY5Y-A53T model of Parkinson's disease: a network pharmacological approach","volume":"2021","author":"He","year":"2021","journal-title":"Evid Based Complement Alternat Med."},{"key":"B26","volume-title":"International Classification of Sleep Disorders","year":"2014"},{"key":"B27","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1159\/000119366","article-title":"A controlled study of 2 doses of idebenone in the treatment of Alzheimer's disease","volume":"36","author":"Weyer","year":"1997","journal-title":"Neuropsychobiology"},{"key":"B28","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/0167-4943(92)90063-a","article-title":"Effects of idebenone in elderly subjects with cognitive decline. Results of a multicentre clinical trial","volume":"15","author":"Bergamasco","year":"1992","journal-title":"Arch Gerontol Geriatr"},{"key":"B29","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1002\/mds.870110510","article-title":"A controlled trial of idebenone in Huntington's disease","volume":"11","author":"Ranen","year":"1996","journal-title":"Mov Disord"},{"key":"B30","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s40263-013-0124-4","article-title":"Mitochondrial enhancement for neurodegenerative movement disorders: a systematic review of trials involving creatine, coenzyme Q10, idebenone and mitoquinone","volume":"28","author":"Liu","year":"2014","journal-title":"CNS Drugs."},{"key":"B31","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1186\/s12974-022-02481-3","article-title":"Parkinson's disease peripheral immune biomarker profile: a multicentre, cross-sectional and longitudinal study","volume":"19","author":"Li","year":"2022","journal-title":"J Neuroinflammation."},{"key":"B32","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1002\/mds.28421","article-title":"Hypomethylation of SNCA in idiopathic REM sleep behavior disorder associated with phenoconversion","volume":"36","author":"Li","year":"2021","journal-title":"Mov Disord."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.3233\/JPD-201912","article-title":"Hypomethylation in rapid eye movement sleep behavior disorder is a potential biomarker for Parkinson's disease","volume":"10","author":"Zhao","year":"2020","journal-title":"J Parkinsons Dis."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.1093\/brain\/awab039","article-title":"Increased free water in the substantia nigra in idiopathic REM sleep behaviour disorder","volume":"144","author":"Zhou","year":"2021","journal-title":"Brain."},{"key":"B35","doi-asserted-by":"publisher","first-page":"e13136","DOI":"10.1111\/jsr.13136","article-title":"Altered structure and functional connectivity of the central autonomic network in idiopathic rapid eye movement sleep behaviour disorder","volume":"30","author":"Li","year":"2021","journal-title":"J Sleep Res."},{"key":"B36","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.sleep.2019.09.015","article-title":"Abnormal intrinsic brain activity of the putamen is correlated with dopamine deficiency in idiopathic rapid eye movement sleep behavior disorder","volume":"75","author":"Li","year":"2020","journal-title":"Sleep Med."},{"key":"B37","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.redox.2015.01.009","article-title":"Border between natural product and drug: comparison of the related benzoquinones idebenone and coenzyme Q10","volume":"4","author":"Gueven","year":"2015","journal-title":"Redox Biol."},{"key":"B38","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1002\/mds.870110510","article-title":"A controlled trial of idebenone in Huntington's disease","volume":"11","author":"Ranen","year":"1996","journal-title":"Mov Disord."},{"key":"B39","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.jconrel.2021.06.024","article-title":"Effectiveness of idebenone nanorod formulations in the treatment of Alzheimer's disease","volume":"336","author":"Huang","year":"2021","journal-title":"J Control Release."},{"key":"B40","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1055\/s-2002-19833","article-title":"Safety and efficacy of idebenone versus tacrine in patients with Alzheimer's disease: results of a randomized, double-blind, parallel-group multicenter study","volume":"35","author":"Gutzmann","year":"2002","journal-title":"Pharmacopsychiatry."},{"key":"B41","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1016\/S1474-4422(07)70220-X","article-title":"Neurological effects of high-dose idebenone in patients with Friedreich's ataxia: a randomised, placebo-controlled trial","volume":"6","author":"Di Prospero","year":"2007","journal-title":"Lancet Neurol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"1748","DOI":"10.1016\/S0140-6736(15)60025-3","article-title":"Efficacy of idebenone on respiratory function in patients with duchenne muscular dystrophy not using glucocorticoids (DELOS): a double-blind randomised placebo-controlled phase 3 trial","volume":"385","author":"Buyse","year":"2015","journal-title":"Lancet."},{"key":"B43","doi-asserted-by":"publisher","first-page":"749336","DOI":"10.3389\/fimmu.2022.749336","article-title":"Idebenone regulates abeta and LPS-induced neurogliosis and cognitive function through inhibition of NLRP3 inflammasome\/IL-1beta axis activation","volume":"13","author":"Lee","year":"2022","journal-title":"Front Immunol."}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2022.981249\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,12]],"date-time":"2022-09-12T07:15:50Z","timestamp":1662966950000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2022.981249\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,12]]},"references-count":43,"alternative-id":["10.3389\/fneur.2022.981249"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2022.981249","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,12]]},"article-number":"981249"}}